Deciphera Pharmaceuticals, Inc. - Common Stock (NQ:DCPH)

25.59 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jun 10, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Deciphera Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

DCPH Stock Earnings: Deciphera Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024 ↗

May 10, 2024

DCPH stock results show that Deciphera Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

Deep Dive Into Deciphera Pharmaceuticals Stock: Analyst Perspectives (5 Ratings) ↗

April 30, 2024

Via Benzinga

S&P 500 Edges Higher; ON Semiconductor Earnings Top Views ↗

April 29, 2024

Via Benzinga

Topics Stocks

Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

April 29, 2024

Via Benzinga

Earnings Scheduled For February 6, 2024 ↗

February 06, 2024

Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of $53.50 billion.

Via Benzinga

Earnings Outlook For Deciphera Pharmaceuticals ↗

February 05, 2024

Via Benzinga

What 4 Analyst Ratings Have To Say About Deciphera Pharmaceuticals ↗

November 20, 2023

Via Benzinga

US Stocks Kick Off The Week In The Green, Tesla Rockets On China's FSD Approval, Yen Rallies: What's Driving Markets Monday? ↗

April 29, 2024

U.S. stocks kicked off the week on a positive note, with all major averages edging higher in anticipation of significant events including earnings reports from tech giants like Amazon.com Inc....

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

April 29, 2024

Via Benzinga

Why Is Cancer Focused Deciphera Pharmaceuticals Stock Skyrocketing On Monday? ↗

April 29, 2024

ONO Pharmaceutical to acquire Deciphera Pharmaceuticals for $2.4B in cash. Deciphera brings specialized R&D in kinase drug discovery, commercial platforms, and a pipeline of cancer drugs including...

Via Benzinga

Earnings Preview: Deciphera Pharmaceuticals ↗

August 08, 2023

Via Benzinga

The Latest Analyst Ratings for Deciphera Pharmaceuticals ↗

May 04, 2023

Via Benzinga

Recap: Deciphera Pharmaceuticals Q1 Earnings ↗

May 03, 2023

Via Benzinga

Preview: Deciphera Pharmaceuticals's Earnings ↗

May 02, 2023

Via Benzinga

Crude Oil Down Over 1%; Deciphera Pharmaceuticals Shares Spike Higher ↗

April 29, 2024

Via Benzinga

Why Is Mullen Automotive (MULN) Stock Up 27% Today? ↗

April 29, 2024

Mullen Automotive stock is climbing higher on Monday with heavy trading of MULN shares alongside it joining a new voucher program.

Via InvestorPlace

Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday ↗

April 29, 2024

Via Benzinga

Citi Just Raised Its Price Target on Shopify (SHOP) Stock ↗

April 29, 2024

Shopify stock is on the rise Monday as shares of SHOP got an increased price target and an upgrade from Citi's analysts this morning.

Via InvestorPlace

Why Is Deciphera Pharmaceuticals (DCPH) Stock Up 72% Today? ↗

April 29, 2024

Deciphera Pharmaceuticals stock is up on Monday after DCPH investors learned of a $2.4 billion acquisition deal with ONO Pharmaceutical.

Via InvestorPlace

Dow Surges Over 100 Points; Domino's Pizza Posts Upbeat Earnings ↗

April 29, 2024

Via Benzinga

Topics Stocks

Deciphera Catapults 72% After Ono Pharmaceutical Agrees To Buy It For $2.4 Billion ↗

April 29, 2024

The company is working on cancer treatments that block problematic kinases by targeting their switch-control pocket.

Via Investor's Business Daily

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

April 29, 2024

Via Benzinga

Deciphera Pharmaceuticals' Investigational Drug Shows Encouraging Response Rates In Rare Type Of Cancer ↗

October 30, 2023

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) announced top-line results from the MOTION Phase 3 study of vimseltinib in patients with Tenosynovial Giant Cell Tumor (TGCT)

Via Benzinga

Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday ↗

October 30, 2023

U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Want to Get Rich? 3 Game-Changing Biotech Stocks to Buy Right Now ↗

August 21, 2023

Biotech stocks may offer some of the most explosive opportunities on the market. Here are three with major catalysts nearing.

Via InvestorPlace

3 Under-the-Radar Biotech Stocks to Buy in 2023 ↗

August 19, 2023

All three biotech companies focus on oncology therapies.

Via The Motley Fool

Why Shares of Deciphera Pharmaceuticals Rose This Week ↗

August 11, 2023

The company's shares rose after the company reported second-quarter earnings.

Via The Motley Fool

Deciphera Pharmaceuticals Sees Renewed Competitive Edge After Theseus Pan-KIT Discontinuation: Analyst ↗

August 10, 2023

Stifel upgraded Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) to Buy from Hold, with a price target of $20 from $14, after reevaluating the competitive landscape for the 2L GIST market.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023 ↗

August 10, 2023

Via Benzinga

Global Payments To Rally Around 17%? Here Are 10 Other Analyst Forecasts For Thursday ↗

August 10, 2023

Keybanc cut the price target for i3 Verticals, Inc. (NASDAQ: IIIV) from $28 to $26. Keybanc analyst Josh Beck maintained an Overweight rating. i3 Verticals shares fell 2.9% to close at $22.76 on...

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.